Rossari Biotech approves ESOP grant, additional investment in Saudi subsidiary

Rossari Biotech Limited's board of directors approved the unaudited standalone and consolidated financial results for the quarter and half-year ended September 30, 2025. The board also approved the grant of 35,000 stock options under the Rossari Employee Stock Option Plan - 2019, with an exercise price of INR 661 per option.

The company further approved an additional investment of up to $8 million in one or more tranches in Rossari International Limited Company (RILC) by March 31, 2027. RILC, a wholly-owned subsidiary incorporated in Saudi Arabia, had nil turnover and SAR 1.00 million net worth as of March 31, 2025, and will engage in chemical manufacturing, trading, distribution, and sales. The additional investment aims to support RILC's business and other requirements.